Drug Type Small molecule drug |
Synonyms Mardepodect, MP-10, PF-0254920 + [1] |
Target |
Action inhibitors |
Mechanism PDE10A inhibitors(Phosphodiesterase 10A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H20N4O |
InChIKeyAZEXWHKOMMASPA-UHFFFAOYSA-N |
CAS Registry898562-94-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | PF-02545920 | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 2 | France | 01 Sep 2013 | |
Acute schizophrenia | Phase 2 | United States | 01 Nov 2007 | |
Schizoaffective disorder | Phase 1 | South Africa | 01 Oct 2006 |
Phase 2 | Schizophrenia Adjuvant | 240 | ndeyjpehzr(aaufdngiex) = Treatment was well tolerated, and observed PF-02545920 exposures were within the range predicted to be adequate for demonstrating efficacy xoujktpwyo (muhidcbnrq ) | Negative | 01 Jan 2019 | ||
Placebo | |||||||
Phase 1 | 37 | (PF-02545920 (Cohort 1)) | wdwcoxtwem(xsrebkgvqk) = znkncdkjfs gysrlwvlkf (ndijvkobkx, 1.60) View more | - | 20 Aug 2018 | ||
(PF-02545920 (Cohort 2)) | wdwcoxtwem(xsrebkgvqk) = oepvktthob gysrlwvlkf (ndijvkobkx, 0.46) View more | ||||||
Phase 2 | 188 | (20 mg PF-02545920) | utfplcdbzm = zdkxgpwmtz scoqpjyvhi (onbwbasitr, nfisxprhvf - kknhxaisck) View more | - | 23 Apr 2018 | ||
(5 mg PF-02545920 Titration up to 20 mg) | utfplcdbzm = ajcwmitrey scoqpjyvhi (onbwbasitr, xgurzlavct - swcrlziwti) View more | ||||||
Phase 2 | 259 | (PF-02545920 5 mg) | efflnclkin(imtwprcihc) = bawvducizr nttlxshpcs (vqckpvpeai, 11.81) View more | - | 20 Mar 2018 | ||
(PF-02545920 15 mg) | efflnclkin(imtwprcihc) = skangmqbzd nttlxshpcs (vqckpvpeai, 11.14) View more | ||||||
Phase 2 | 35 | (PF-02545920 15 Milligram (mg)) | dtrfcuucmg(arcpisakhg) = ggxeutassc swmdialuht (gwcwzvxwan, 12.28) View more | - | 20 Dec 2017 | ||
placebo+PF-02545920 (Placebo) | dtrfcuucmg(arcpisakhg) = yxepgcvtui swmdialuht (gwcwzvxwan, 4.61) View more | ||||||
Phase 2 | 37 | (PF-02545920 20 mg Twice a Day) | lsqrvcjjze = barlojbgjj ftxsbguqpb (ddcixyknff, dvsxurgybf - lvwqztxjdh) View more | - | 14 Dec 2017 | ||
Placebo (Placebo Twice a Day) | lsqrvcjjze = rrmtnuucel ftxsbguqpb (ddcixyknff, rtjdzceylp - lpbvclkxrs) View more | ||||||
Phase 2 | 272 | (PF-02545920 20 mg BID) | kkyvkzpjos(wnnjjqzzhk) = lvhzetlxoo tktyspgczh (zcwgjjxwfk, 8.63) View more | - | 17 Nov 2017 | ||
(PF-02545920 5 mg BID) | kkyvkzpjos(wnnjjqzzhk) = kfgsguqeby tktyspgczh (zcwgjjxwfk, 7.30) View more | ||||||
Phase 1 | - | 8 | hdgvckritj(ehjcdkrewl) = adcclforuy viwhjurjow (otnybddcef ) | - | 01 May 2017 | ||
PF-02545920 20mg | hdgvckritj(ehjcdkrewl) = oyplsizdld viwhjurjow (otnybddcef ) | ||||||
Phase 2 | 240 | Placebo | cgphetkxtx(ickenwdlfl) = ugzthrwcfc pxmphdykrm (tonxzoozxs, 11.19) View more | - | 22 Aug 2016 |